1xbet 카지노., Ltd.

1xbet 카지노., Ltd. (Otsuka) and Takara Bio Inc. (Takara Bio) announce that the clinical development program for gene therapy drug candidate NY-ESO-1・siTCR^TMhas received the Orphan Regenerative Medicine designation by the Ministry of Health, Labour and Welfare in Japan. NY-ESO-1/siTCR^TMis in development 1xbet 카지노 synovial sarcoma.

Takara Bio, the originator of NY-ESO-1/siTCR^TM, is co-developing this candidate with 1xbet 카지노 based on a co-development and exclusive sales agreement covering Japan signed in April 2018.

NY-ESO-1/siTCR^TM(development code: TBI-1301, and international nonproprietary name: mipetresgene autoleucel) is a TCR gene transfer T-cell therapy (TCR T-cell therapy).